Tivoxavir Marboxil - The Prophylactic Flu Drug American Agencies and Elites Are Claimed to be Hoarding in Secrecy
Thailand Medical News Exclusive: Secret Weapon Against Flu Viruses
In a stunning revelation that’s raising serious questions about transparency and biosecurity, a powerful new prophylactic flu treatment called Tivoxavir Marboxil (Tivor) is reportedly being kept under wraps by select American government agencies and billionaire elites. This investigational drug, designed to act as a one-time preventive prophylactic drug or as a treatment drug against deadly influenza strains like H5N1 bird flu and drug-resistant seasonal flu, has completed its Phase 2 clinical trial in secret according to claims by certain sources—yet no public disclosures or peer-reviewed data have surfaced to confirm its results.
A new flu drug is being secretly stockpiled by elites while the public remains uninformed of its
existence and potential benefits
While the world continues to grapple with evolving strains of influenza like the current flu surge driven by a new mutated H3N2 strain belonging to the K Clade and experts remains on edge about potential zoonotic pandemics, whispers from pharmaceutical insiders suggest Tivoxavir Marboxil is already being mass-produced under covert government contracts. Unverified sources allege that since October 2025, the U.S. has been rapidly stockpiling the drug under undisclosed emergency health directives, while the general public remains unaware of its existence. Thailand Medical News was informed of these developments by certain European oligarchs residing in New York and managed to procure a sizeable stock for personal use in case of emergencies.
A Game Changing Antiviral Hidden in Plain Sight
Tivoxavir Marboxil (TXM), developed by Traws Pharma, a new leader in the biotech and pharma industry with lots of reported exciting drugs in the pipeline, and accelerated by Expert Systems’ AI-powered discovery platform, targets the CAP-dependent endonuclease (CEN) enzyme—one of the most highly conserved and essential viral proteins across influenza strains. In Phase 1 trials, TXM was shown to maintain effective antiviral blood levels for up to three weeks with just a single dose, demonstrating not only safety but potentially groundbreaking efficacy.
https://www.clinicaltrialvanguard.com/news/traws-pharma-reports-positive-bird-flu-results-for-tivoxavir/
This
Medical News report highlights how the drug’s preclinical trials, conducted in ferrets, mice, and non-human primates exposed to the lethal H5N1 virus, showed dramatic protection against death and disease. What makes the story more unsettling is that these trials involved a strain directly isolated from an American dairy worker infected with bird flu—suggesting there may be more concern behind closed doors than officials are admitting.
What We Know and What They Are Not Telling Us
Though officially only Phase 1 results were publicly discussed, internal leaks according to unverified sources claim tha
t Phase 2a trials began quietly in mid-2025—and are now believed to have been completed. However, no data from these trials have been released, no press conferences held, and no mentions of results appear in clinical registries. Instead, according to claims, production appears to have ramped up in silence, with expert sources reporting that manufacturing facilities in the Midwest have been operating under Department of Defense oversight.
Meanwhile, individuals tied to major pharmaceutical lobbying groups and ultra-wealthy figures who have funded various biodefense initiatives are allegedly already in possession of personal supplies of the drug—long before it reaches hospitals, clinics, or international humanitarian programs.
A Billion Dollar Opportunity for the Few
The market implications are staggering. Tivoxavir Marboxil is poised to become a multi-billion-dollar asset in pandemic preparedness programs, particularly in the U.S., which has a track record of hoarding medical supplies during public health crises. Discussions with the Biomedical Advanced Research and Development Authority (BARDA) regarding TXM’s inclusion in national emergency stockpiles are reportedly underway, but once again, no official details have been made public.
Documents obtained through industry channels according to sources, hint that an Investigational New Drug (IND) application was submitted specifically for fast-tracked stockpiling clearance. In parallel, claims have been made that surveillance and acquisition contracts have allegedly been signed with a small number of high-level private healthcare logistics firms tasked with quiet distribution—should an outbreak demand rapid deployment.
Why the Silence Matters
The absence of public disclosures and transparent regulatory updates raises serious ethical questions. In a world where global cooperation is vital to combat zoonotic viruses, a potential best-in-class drug that could save millions is being quietly funneled into the hands of a select few. While health officials emphasize global solidarity, actions behind the scenes tell a far different story.
It also raises questions as to whether or not certain American defense agencies are planning their own biological attacks in other parts of the world with possibly serial-passaged or enhanced or recombined influenza virus strains.
Tivoxavir Marboxil represents a powerful tool that could change the global approach to pandemic flu response. Yet the secrecy surrounding its development, trial results, and stockpiling hints at a deeper concern within elite circles—perhaps that a major outbreak is more imminent than the public is being told.
If these allegations are true, it reflects a disturbing pattern of elite preparedness at the expense of public transparency. It also suggests that when the next flu pandemic hits, access to life-saving drugs like TXM might be decided by privilege rather than need.
For the latest on Influenza, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/influenza-or-flu
(Not part of this article may be reproduced or published without due credit to Thailand Medical News and the compulsory usage of the URL link to the original article by Thailand Medical News.)
Share
Tweet
Share
